Associations of liver function with plasma biomarkers for Alzheimer’s Disease

• DOI: 10.1007/s10072-023-07284-9
• Publication Date: 2024-01-05T00:02:16Z
• Authors: Bin Zhang; Cheng Zhang; YuYe Wang; LeiAn Cheng; Yu Wang; YaNan Qiao; Dantao Peng
• Keywords: Male; Aged, 80 and over; Amyloid beta-Peptides; tau Proteins; Alanine Transaminase; Bilirubin; Alkaline Phosphatase; Peptide Fragments; Cohort Studies; Cross-Sectional Studies; Liver; Liver Function Tests; Alzheimer Disease; Neurofilament Proteins; Humans; Female; Aspartate Aminotransferases; Biomarkers; Aged

Blood-based biomarkers for Alzheimer's disease (AD) are promising to be used in clinical settings. The liver is an important degradation organ of the body. Whether liver function affects the levels of AD biomarkers needs to be studied.To investigate the associations between liver function and the plasma levels of AD biomarkers.We conducted an ADNI cohort-based cross-sectional study. Thirteen liver function markers commonly used in clinical settings were analyzed: total protein (TP), albumin (AL), globulin (GL), AL/GL ratio (A/G), total bilirubin (TB), direct bilirubin (DB), indirect bilirubin (IB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), AST/ALT ratio, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), and γ-glutamyltransferase (GGT). Liquid chromatography-tandem mass spectrometry was used to detect the plasma Aβ42 and Aβ40 concentrations. Single Molecule array technique was used to measure the plasma p-tau181 and NfL concentrations. We used linear regression models to analyze the associations between liver function markers and the levels of AD plasma biomarkers.ALP was positively associated with the levels of plasma Aβ42 (β = 0.16, P = 0.018) and Aβ40 (β = 0.21, P = 0.004). LDH was positively associated with the levels of plasma p-tau181 (β = 0.09, P = 0.022). While NfL was correlated with multiple liver function markers, including AL, A/G, ALT, AST/ALT, and LDH.Liver function was associated with the plasma levels of AD biomarkers. It needs to consider the potential influence of liver function on the reference ranges and the interpretation of results for AD biomarkers before clinical use.